ArticleDiabetology & metabolic syndrome2025
Stress hyperglycemia ratio: a novel prognostic marker in chronic kidney disease.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Unveiling the relationship between stress-hyperglycemia ratio and cardiometabolic multimorbidity risk using interpretable machine learning.European journal of medical research · 2026Article
- Article
- Simultaneous assessment of stress hyperglycemia ratio and glucose variability to predict all-cause mortality in sepsis patients across different glucose metabolic states: an observational cohort study with interpretable machine learning approach.International journal of surgery (London, England) · 2026Observational
- Novel obesity biomarkers as mortality predictors in individuals with CKD: a comparative analysis with traditional anthropometric measures.Renal failure · 2025Article
- The prognostic significance of stress hyperglycemia ratio in evaluating all-cause and cardiovascular mortality risk among individuals across stages 0-3 of cardiovascular-kidney-metabolic syndrome: evidence from two cohort studies.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe stress hyperglycemia ratio (SHR) has recently been suggested to characterize acute glycemic rise better than the admission blood glucose and to be associated with unfavorable outcomes in patients with various cardiovascular diseases. This study aimed to explore the associations between SHR and all-cause or cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD).
methodsAdults with CKD participating in the 1999-2018 US National Health and Nutrition Examination Survey with complete SHR and follow-up data were included. SHR was calculated from fasting blood glucose and glycated hemoglobin levels. Associations between SHR and mortality were investigated by weighted multivariable Cox regression analysis.
resultsAmong the 3284 participants (mean age 61 years, men prevalence 44.09%) included, 1324 (487 CVD-related) deaths occurred during a median follow-up of 87 months. The restricted cubic spline curve adjusted for all covariates showed a U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, with discernible inflection points at 0.86 and 0.88, respectively. The hazard ratio (95% confidence interval) was 0.117 (0.034-0.404) for SHR < 0.86 and 2.065 (1.328-3.209) for SHR ≥ 0.86 for all-cause mortality, and 0.063 (0.008-0.531) for SHR < 0.88 and 1.551 (0.770-3.124) for SHR ≥ 0.88 for CVD mortality.
conclusionWe identified U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, in patients with CKD. This result highlights that SHR may be potentially informative for the risk stratification of CKD patients. Given the potential limitations of residual confounding, prospective studies are needed to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.